by Grow Up Conference | Sep 19, 2023 | Media Partners, Stratcann
The number of Canadians who reported ever smoking or vaping cannabis did not increase from 2021 to 2021, according to new figures from the federal government.
The figures are part of new survey results released by Health Canada’ Canadian Tobacco and Nicotine Survey (CTNS) 2022. The survey measures the prevalence of cigarette smoking, vaping, cannabis, and alcohol use among Canadians aged 15 years and older and is conducted by Statistics Canada on behalf of Health Canada. The data this year also includes figures on cannabis edibles.
The results are based on responses to an electronic questionnaire or a telephone follow-up interview from 12,133 respondents across all 10 provinces, which represents a weighted total of 32 million Canadian residents aged 15 years and older.
While about 40 percent of Canadians aged 15 and older reported ever smoking cannabis in 2022, only around 10 percent reported doing so in the past 30 days. Just over 12 percent reported ever vaping cannabis, while those who reported vaping cannabis in the past 30 days was about five percent. All of these figures are similar to those reported in 2021.
About six percent of Canadians aged 15 and older reported consuming cannabis edibles in the past thirty days.
Just over three percent of Canadians aged 15 and up reported daily smoking of cannabis in 2022, down from four percent in 2021. One percent of Canadians over the age of 14 reported vaping cannabis on a daily basis, unchanged from the previous year. Fewer than 1 percent of this same group reported consuming cannabis edibles on a daily basis.
Demographics
Those Canadians with less than a high school education were less likely to report using cannabis in the past 30 days (including those still in school), while those with secondary education but no post-secondary education were the most likely to consume in any of the three reported forms.
Those who identified as visible minorities reported lower levels of smoking, vaping, or eating cannabis in the past 30 days, but the reported use of vaping and smoking cannabis was higher among those Canadians who identify as Indigenous than those who did not. Consumption of edibles was not higher amongst those identifying as Indigenous.
Those Canadians aged 15 and up who identified as lesbian, gay, bisexual, or another sexual orientation that is not heterosexual (LGB+) were more likely to report smoking, vaping, and consumption of cannabis edibles in the past 30 days.
In general, Canadians over the age of 14 years who reported using cannabis were more likely to be those who reported their “general health” and “mental health” as “fair” or “poor” compared to those who rated it as excellent, very good or good.
Those Canadians with a disability were also more likely to report cannabis use than those that did not report a disability.
Related Articles
by Grow Up Conference | Sep 19, 2023 | Media Partners, Stratcann
BZAM, a Canadian licensed producer behind several successful brands, has let more than 90 personal go as part of a corporate restructuring and the recent sale of several facilities in BC.
The company also says it is “focusing the scope of activities” at its facility in Pitt Meadows, BC facility and “concentrating other activities at its Ancaster, ON facility” as part of its final phase to “unlock company-wide synergies” following its merger with Ontario-based The Green Organic Dutchman (TGOD) in 2022. TGOD’s (now BZAM) greenhouse is located in located in Ancaster, near Hamilton.
At the time, the merger was touted as a way to emphasize TGOD’s market strength in Quebec and Ontario with BZAM’s strong presence in western Canada. A representative with BZAM confirmed with StratCann, via email, that the layoffs occurred Monday, Sept 18.
BZAM’s Pitt Meadows facility was said, at the time, to provide TGOD with low-cost THC distillate and extraction capabilities.
In their most recent quarterly report in August, BZAM said it had recently sold its facilities in Midway, BC and Maple Ridge, BC and references a focus in 2023 on “streamlining” operations. It also refers to the recent divestment in their Puslinch, ON facility and Edmonton, AB facility. BZAM had previously purchased a hotel in Midway to house its employees of the outdoor farm near the US border.
However, the same quarterly report referred to the Pitt Meadows facility as one of its two “core” facilities, the other being the Ancaster, ON acquired through the merger with TGOD.
BZAM’s plan included getting rid of what it called “redundant facilities” and focussing production activities on its remaining sites, as well as reducing “selling, general, and administrative expenses,” which it notes include reducing its headcount “by more than 90 additional personnel.”
BZAM recently posted several job listings for its Pitt Meadows and Hamilton (Ancaster) sites.
by Grow Up Conference | Sep 19, 2023 | Grow Opportunity, Media Partners
(Globe Newswire) Vancouver — EnWave Corporation announced today that it has approved the acquisition of Eregli Agrosan, a Turkish licensor of the company’s Radiant Energy Vacuum (REV) dehydration technology, by Alarko Tarim Sanayi ve Ticaret, which is a subsidiary of Alarko Holdings A.S., one of the largest and most respected business conglomerates in Turkey.
Alarko has acquired 100 per cent of Eregli and has been assigned the existing license between EnWave and Eregli.
Alarko intends to make material investments into Eregli to expand its drying business and further improve the commercialization of their REV-dried product portfolio. Eregli currently produces an extensive list of dried fruit, vegetable and dairy products using REV technology.
by Grow Up Conference | Sep 19, 2023 | Grow Opportunity, Media Partners
(Globe Newswire) KENT, Wash., — Custom Cones USA, the cannabis industry experts in pre-rolls, pre-roll packaging, and pre-roll manufacturing solutions, today released a report revealing that pre-rolls emerged as the second-largest product category in Canada, poised to overtake flower as the leading category. Notably, infused pre-rolls have seized the spotlight with a staggering growth rate of nearly 606 per cent over the past year. Specifically, infused pre-rolls grew from 6.2 per cent of total sales in January 2022 to an incredible 29.8 per cent of total sales by February 2023, a growth rate of nearly 606 per cent.
In 2022, Canada Experienced a 54 per cent increase in pre-roll sales revenue
The Canadian pre-roll segment continues to experience robust growth, with total pre-roll revenues exceeding CAD$1 billion in 2022, reflecting a staggering increase of more than 54 per cent. This remarkable surge in sales was observed across every tracked province, from Saskatchewan and Alberta, which saw growth rates of 33 per cent and 37 per cent, respectively, to British Columbia, with nearly 54 per cent growth, and a remarkable 69 per cent increase in Ontario, the country’s most populous province. One major growth driver is the increase in sales of the pre-rolls, particularly infused pre-rolls.
Pre-rolls emerge as the second-largest product category in Canada
According to industry data, pre-rolls have become the second-largest category in Canada, capturing a 28.9 per cent market share over the first five months of 2023, marking a year-over-year growth of 23.5 per cent.
According to Headset data, in 2022, pre-roll products accounted for 27 per cent of the new items introduced in the Canadian market, demonstrating a remarkable growth rate of 48.2 per cent compared to 2021, second only to beverages. In response to the increasing demand in this category, a total of 1,870 new pre-roll products were launched in the Canadian market during that year.
Pre-rolls are poised to overtake flower as the leading product category in Canada
The data reveals a significant shift in consumer preferences, with pre-roll sales in Canada surging by more than 50 per cent over the past 18 months. Pre-rolls have witnessed a substantial increase in market share, rising from 20.7 per cent in early 2022 to an impressive 31.5 per cent by mid-2023. Concurrently, the market share of flower has steadily declined from over 45 per cent to slightly over 35 per cent during the same period. At this rate, pre-rolls will soon become the most popular product category in Canada.
Health Canada’s stringent regulations initially limited the availability of infused pre-rolls, but a rule clarification in late 2021 opened the doors to these products. As a result, infused pre-rolls have experienced explosive growth, increasing by a remarkable 1,426 per cent from 2021 to 2022. This segment’s rapid expansion, driven by consumer demand for connoisseur pre-rolls that combine concentrates with ground flower, has had a profound impact on the Canadian cannabis market.
Pre-rolls exhibit the least amount of price compression in both the U.S. and Canada
The resilience of pre-roll prices can be partially attributed to their manufactured nature and the unique attributes of infused pre-rolls. The demand for stronger pre-rolls, coupled with declining prices for flower and concentrates, has created a favorable environment for launching infused pre-roll products.
“The surge in popularity of infused pre-rolls, with their higher price point, has been a significant factor contributing to the increase in the average price of Canadian pre-rolls,” said Harrison Bard, co-founder and CEO of Custom Cones USA. “This trend has been instrumental in maintaining the overall price of pre-rolls even as prices for flower and concentrates have decreased.”
After taking a closer look at the data, it is clear that Canada is not only seeing incredible growth in the pre-roll market, but they are setting the pace for infused pre-roll growth for the entire industry. As pre-roll manufacturing equipment evolves and the costs of flower and oil decline, producers are now capable of manufacturing infused pre-rolls at only a slight premium over regular pre-rolls. Consequently, as consumers are presented with this choice, an increasing number are opting for the infused variety, resulting in heightened sales within the category and greater revenues for both producers and retailers.
by Grow Up Conference | Sep 19, 2023 | Cannabis News Wire, Media Partners
Nearly two years after President Joe Biden took office, policy experts and drug-reform advocates aren’t happy with the Biden administration’s efforts to fulfill the campaign’s cannabis promises. Last month, the Biden administration recommended that the U.S. Drug Enforcement Administration (DEA) reclassify marijuana and asked federal drug officials to consider removing the decades-long restrictions on marijuana.
The Department of Health and Human Services (HHS) issued the cannabis rescheduling recommendation to the DEA after President Biden sent a request to the HHS calling for a review of the rescheduling of marijuana as a Schedule I drug with no medical application.
Schedule III drugs are defined as chemicals or substances such as codeine, ketamine and anabolic steroids with a low to moderate risk of psychological and physical dependence and less abuse potential compared to Schedule I drugs like cocaine or heroin.
However, the administration’s efforts to reform federal cannabis policies haven’t drawn much praise from policy experts and advocates. According to the National Association of Black Cannabis Lawyers, reclassifying cannabis under the Controlled Substances Act will not address the racial justice issues associated with current marijuana laws.
The association’s executive director Natacha Andrews explained that federal rescheduling does not deal with the harm federal criminalization caused to marginalized communities, over policing by law enforcement, immigration issues or increased access to key federal services.
Furthermore, Andrews said the recommendation to reschedule cannabis did not align with what dozens of states had done to legalize and regulate marijuana. Current federal law classifies cannabis in the same group as drugs such as cocaine and methamphetamines, which have no medical applications unlike cannabis and have significantly deadlier side effects on the body.
Policies instituted decades ago honed in on cannabis as a societal problem and emboldened law enforcement and the court system to be incredibly harsh on cannabis offenders. Whether by design or not, individuals from Black and Brown communities bore the brunt of America’s intense cannabis policing despite using cannabis at similar rates to White people.
Most states with legal cannabis programs have now included social-equity provisions to invest in communities that were disproportionately affected by the war on drugs. However, many aren’t satisfied with the federal government’s cannabis reform efforts.
Cat Packer, the Drug Policy Alliance’s director of drug markets and legal regulation, noted that the administration is delivering less than what it promised during presidential campaigns. She said the recent recommendation for federal rescheduling left her wondering how the president will keep his campaign promise of decriminalizing the personal use of cannabis. The entire cannabis industry, including companies such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF), hope that federal restrictions on marijuana are eased so that they can have access to a bigger market.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Sep 18, 2023 | Media Partners, Stratcann
Alberta Gaming, Liquor and Cannabis (AGLC) says it will be relisting CBN and THCV products.
In a letter to licensed producers today, the AGLC now says it will be reversing a recent policy change to include CBN and THCV in THC totals, saying it was based on a misinterpretation of federal messaging.
The letter, which was sent to producers who sell products within the province early in the afternoon on September 28, says that “effective immediately” the AGLC “will relist and accept new products that contain these cannabinoids, and will not include CBN and THCV when determining THC totals until clear direction is provided by Health Canada.”
In mid August, the AGLC contacted at least some producers, informing them that it would be including the amount of CBN and/or THCV in a cannabis product within the total THC. This covered any edibles that had more than 10mg total of THC, CBN, and/or THVC per serving or per package. It would also apply to the 1000mg THC limit for extracts, including vape pens.
Several products sold in Alberta would have been impacted, including one micro producer who was informed of the change via email, being told that all their products would be removed from shelves.
The AGLC had initially told StratCann that the decision to include CBN and THVC within the total THC amounts was based on messaging from Health Canada and had been implemented by several other provinces, including the OCS.
However, four separate provincial cannabis agencies, including in Ontario, confirmed with StratCann that they have no such policy in place, as did a representative from Health Canada.
The AGLC now says it interpreted the information it had received from Health Canada “to mean measures were immediately needed to curtail the supply of products with minor intoxicating cannabinoids” in order to protect Albertans from the risk of overconsumption.
In March of this year, Health Canada reached out to the cannabis industry seeking feedback on potential amendments to Cannabis Regulations, including whether the “limits on the maximum quantity of delta-9-THC contained in a cannabis product (by container and ingestible unit) apply to the sum total of all intoxicating cannabinoids found in the product.” It did not reference CBN specifically.
Sources close to the issue say the federal health agency has also floated a draft document to stakeholders with guidelines for licensed producers on the subject of these minor “intoxicating cannabinoids” such as Delta-8 THC, THC-V, and CBN, among others. However, no licensed producers StratCann has spoken to for this topic have received official guidance from Health Canada on this subject in reference to including CBN within the existing THC limit for products like edibles.
The AGLCs policy on including delta-8 and delta-10 in the total THC remains in place.
“We apologize for any inconvenience and will continue to do our best to keep Alberta’s cannabis industry vital and sustainable,” says the letter sent to producers from the AGLC.
Related Articles
by Grow Up Conference | Sep 18, 2023 | Cannabis News Wire, Media Partners
A recent study in the “PLoS ONE” journal found that more than 2,300 individuals with persistent health issues experienced improved well-being and reduced fatigue within the first three months of using medicinal cannabis. The study was centered on the responses obtained from eligible Australian patients who participated in the QUEST Initiative.
The participants’ age spectrum spanned from 18 to 97 years of age, with an average age of 51. Among the participants, 62.8% were women while 37.2% were men. The majority of participants reported experiencing chronic pain (69%), followed by insomnia (23%), anxiety (22%), and a combination of anxiety and depression (11%).
Before starting cannabis treatment, the participants were tasked with completing initial surveys concerning their health-related quality of life (HRQL), pain levels, sleep patterns, fatigue levels, and depression and anxiety symptoms. Subsequent follow-up surveys were administered at the two-week mark and then on a monthly basis for three months.
All participants were prescribed Little Green Pharma’s medical marijuana oil, comprising CBD and THC dissolved in MCT oil. This product was available in four different formulations featuring varying THC-to-CBD ratios: 1:20, 10:10, 20:5 and CBD only.
When compared to initial baselines, patients who faithfully adhered to the three-month treatment regimen reported notable enhancements in their overall health-related quality of life. In contrast, individuals who only completed the first follow-up assessment demonstrated less progress compared to those who persisted with the treatment.
With regard to pain management, the study revealed that participants, on the whole, exhibited improvements in pain-related metrics. The magnitude of improvement, however, was more pronounced among those diagnosed with chronic pain conditions compared to those not receiving pain-focused treatment.
Sleep patterns did not witness any significant amelioration among the respondents; nevertheless, a reduction in fatigue levels was noted, signifying clinically meaningful improvements.
Regarding depression, the research disclosed that while scores shifted from moderate to mild severity, they failed to reach the five-point threshold indicative of clinically meaningful improvement. However, substantial improvement was observed among individuals diagnosed with specific conditions.
Anxiety scores displayed analogous trends, revealing significant improvements over time but falling short of reaching the expected threshold, except in cases where participants were diagnosed with anxiety conditions.
Throughout the three-month period, a total of 127 participants formally withdrew from the study, citing various reasons for doing so. These included perceived ineffectiveness of the treatment, alterations in treatment plans, unwanted side effects and the perceived high cost of cannabis products. However, the majority reported at least some degree of relief from their ailments.
Despite the generally favorable outcomes, the researchers acknowledged that certain reported improvements might be attributed to the placebo effect.
Looking ahead, the study intends to continue tracking patients for a full 12 months to assess the sustainability of the observed improvements in patient-reported outcomes. Additionally, further subgroup analyses will be conducted to ascertain whether patients with specific conditions experience superior outcomes when evaluated using condition-specific questionnaires.
This study pointing to the beneficial effects of medical marijuana could be good news to companies that are looking to popularize their medicinal cannabis products in different markets around the world, such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF).
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Sep 18, 2023 | Media Partners, Stratcann
The BC government should take lessons from one of the province’s only indoor cannabis consumption spaces, says a new research paper.
An indoor consumption lounge inside one of Canada’s oldest compassion clubs offered members a chance to consume cannabis in a safe space, with the club itself serving as an example of a community-based model of cultivation, distribution, and consumption, says the study.
The study was recently posted in the peer-reviewed journal, Contemporary Drug Problems, which publishes research on alcohol and other psychoactive drugs, licit and illicit. The authors present a case study of the Victoria Cannabis Buyers Club (VCBC) and its consumption space, affectionately called “The Box”.
The Box was a small room inside the VCBC’s former location that was used as a cannabis consumption space by many of the club’s members. The Box closed in February 2023 when the VCBC was forced to move locations due to enforcement from the province, but the research paper argues it can serve as an example for the province as it continues to look at cannabis consumption spaces.
With research beginning in 2021, The Box was at the time closed due to pandemic-related restrictions, but information was collected through a survey sent out to members. The survey was open between January and March 2022 and was completed by 104 respondents. Although the club says they have 8,000 members, the number of current, active members is not provided.
Survey results showed members used The Box for an array of reasons, from socializing to learning more about cannabis. Respondents reported using The Box as often as several times a day to one or two times a month. Many reported using the space because of a lack of space to consume at home, with smoking being the most common mode of consumption.
The BC government can learn from this model, concludes the research paper, especially given that the government is currently looking at rules for consumption spaces. Although those potential rules will specifically exclude indoor smoking and vaping, the usefulness of these spaces for those using cannabis for therapeutic purposes needs to be taken into account, it says.
Related Articles
by Grow Up Conference | Sep 18, 2023 | Media Partners, Psychedelic News Wire
Recent research published in the “International Journal of Mental Health and Addiction” has indicated that psychedelic use may result in reduced cocaine intake. The study found that while psychedelic users reported either reducing or completely stopping their intake of cocaine, antidepressants and alcohol, their use of tobacco and cannabis products went up.
As psychedelics have been illegal at the state and federal levels for the past several decades, their use has been limited to a small niche community of psychonauts. However, a recent surge in psychedelic research revealed that hallucinogens have the potential to treat a myriad of mental-health disorders and caused public interest in psychedelics to surge.
The growing body of literature indicates that psychedelics such as psilocybin, LSD and ayahuasca may be able to offer long-term relief against mental disorders such as post-traumatic stress disorder (PTSD), anxiety and treatment-resistant depression with barely any adverse side effects. Furthermore, several indigenous communities from around the world have a long and rich history of using psychedelics in spiritual, cultural, and religious rituals. As this information has come to light, more people have begun using psychedelics either recreationally or for therapeutic purposes.
A June study from Colu found that past-year use of non-LSD psychedelic use among young adults in the United States aged 19 to 30 years old doubled from 2018-–2021. This surge in psychedelic use seems to have varying impacts on how Americans use other types of drugs. Study author Kevin F. Boehnke and his team used data from the Canadian Psychedelic Survey, a survey designed to collect data on the use of 11 psychedelic substances among adults aged 19 years and older, to study psychedelic-use patterns and how those patterns affect the use of other psychoactive drugs.
The research team theorized that psychedelic use would result in reduced tobacco and alcohol intake.
Researchers found that 44% of people decreased their alcohol use or stopped drinking after they started using psychedelics, 43% decreased antidepressant use or stopped using them altogether, and 43% reduced or stopped using cocaine. However, 14% of the study participants reported starting or increasing their use of other drugs, 11% increased their cannabis use, 9% consumed more tobacco, and 4% said they began using methamphetamine. Interestingly, participants who reported using less psychoactive substances after psychedelics tended to be younger.
Participants who were using psychedelics for therapeutic purposes were much more likely to report reducing the use of other drugs, with psilocybin (magic mushrooms) being especially influential in inducing reduced drug use in 58% of the participants.
When startups such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) finally have their psychedelic formulations approved by the FDA and other regulators, patients will have psychedelic treatments whose safety profile and drug interactions are known. This could reduce the risks associated with taking multiple substances without knowing the potential risks of such combinations.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
by Grow Up Conference | Sep 18, 2023 | Media Partners, Oaksterdam University
Oaksterdam University counts 80,000 alumni in 110+ countries among our ranks of cannabis success stories. Writer A.J. Herrington, well known for his articles in top cannabis publications, is among them.
A.J. Herrington is among the top cannabis journalists in the field, writing daily for publications like High Times, Forbes and CannabisNow. He credits landing his first assignment thanks to Oaksterdam University.
“When I pitched my first story to High Times, I mentioned I was an Oaksterdam graduate. It obviously didn’t hurt,” A.J. says.
Oaksterdam Alumni and Journalist A.J. Herrington.
A career in cannabis
After years of working in retail, A.J. became interested in entering the cannabis industry during the campaign for Proposition 64, which would legalize adult-use cannabis in California. Being an avid cannabis consumer and having experience growing his own, A.J. believed that Proposition 64 would pass and create a massive legal market for cannabis in his home state.
“With Prop 64, I thought to myself, this is going to pass and it’s going to be huge – the biggest legal market for cannabis in the country. I wanted to be a part of it,” A.J. says.
A.J. began researching the burgeoning industry and discovered Oaksterdam University while browsing online. He enrolled in a four-day intensive at the school’s campus in Oakland, Calif. Impressed by his experience there, he signed up for Oaksterdam’s four-day cultivation seminar in Las Vegas, which coincided with the passage of Proposition 64 in November 2016. A.J. originally intended to enter the cultivation industry once job opportunities became available, but his career took an unexpected turn.
“I saw on the news that the San Diego City Council was going to be considering legalizing cannabis businesses in city limits,” A.J. says. “This was a big news story for cannabis because San Diego is the second-largest city in the state. What they do could set a trend as to what other cities do.”
Seizing the opportunity, A.J. wondered whether High Times would be interested in a story about the San Diego City Council‘s deliberations. He had some experience writing for a nonprofit organization, and felt confident pitching a story to the renowned cannabis publication.
“Almost right away, an editor got back to me and said they would be interested,” A.J. says.
The city council meeting turned out to be controversial, lasting a grueling 10 hours. “So many people had signed up to speak, mostly in favor of the ordinance but many people against it,” A.J. says. “I went home, wrote the story the next day, and sent it in.’”
This marked the beginning of A.J.’s journey in cannabis journalism. A.J. pitched more stories to High Times, gradually increasing his contributions from one article per week to nearly one per day.
A.J.’s talent, discipline, and growing expertise led to offers from other publications like Forbes and CannabisNow, which he attributed to the foundation he gained from Oaksterdam and his early experiences at High Times.
Edwin Nutting cares for his hive at his home in Santee, Calif. (Photo courtesy A.J. Herrington/High Times)
Stories from the leading edge
Throughout his career, A.J. has had the opportunity to cover many fascinating stories. One of his favorite assignments was covering a beekeeper who collaborated with a medical marijuana provider to create cannabis-infused honey. A.J. put on a bee suit, captured the honey harvesting process through words and photos, and shared the story.
Another highlight was his investigation into the challenges faced by Native American tribes in entering the regulated cannabis market in California. Assigned by the team at High Times, A.J. dedicated weeks to research, interviews, and even visited a reservation in San Diego County to gather firsthand information from a tribe that repurposed their casino space for cannabis businesses on their land.
Today, A.J. continues to thrive in his career as a writer. With multiple clients and daily assignments, he balances his professional life with his passion for cultivating cannabis in his own home garden.
Social media also plays a significant role in A.J.’s work, allowing him to connect with a broader audience and share the latest developments in the cannabis industry. His journey from retail to cannabis journalism stands as a testament to the power of pursuing one’s passions and seizing opportunities in a rapidly evolving field.
Recent Comments